Skip to main content

Dr. Jad Kebbe, M.D.

Pulmonology (Pulmonary Disease Physician)

  • Medicare participating

At a glance

Years since graduation
17
In the NPI registry since
2010
Medicare patients seen, 2024
200

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2010Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Pulmonary Disease Physician primary
    OK license 31942
  • Critical Care Medicine (Internal Medicine) Physician
    OK license 31942

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Pulmonology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
200
Services billed
1,066
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Critical care, first 30-74 minutes15665
Established patient office or other outpatient visit, 40-54 minutes13286
Test to examine how well the lungs exchange gases11166
Test to determine lung volumes using sensors9363
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes8958
Test to measure expiratory airflow and volume7955
Established patient office or other outpatient visit, 30-39 minutes5743
Test to measure largest amount of air breathed in an out3532
Test to measure expiratory airflow and volume changes before and after medication administration2926
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes2717

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 4 companies reported 8 payments worth $866 in total to this clinician.

By type
Consulting Fee$450
Food and Beverage$416

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Aug 25, 2025Vertex Pharmaceuticals Incorporated
Aug 25, 2025
Consulting Fee$450

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Oklahoma →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $640,827 in research payments for these studies, mostly to the institutions running them.

  • A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
    E.r. Squibb & Sons, L.l.c.
  • Idiopathic Pulmonary Fibrosis Prospective Outcome Registry
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • Phase 2 Double Blind Randomized Study in IPF and SSc ILD
    Genentech, Inc.
  • A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
    E.r. Squibb & Sons, L.l.c.
  • Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
    United Therapeutics Corporation · Completed · NCT04708782
  • Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
    United Therapeutics Corporation · Enrolling by invitation · NCT04905693
  • Ph iii study to evaluate the efficacy and safety of astegolimab in copd
    Genentech, Inc.
  • A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with id…
    Boehringer Ingelheim Pharmaceuticals, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Pulmonology clinicians in Oklahoma City

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 11, 2016), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1487968418. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.